Similar articles

• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

  Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Barnett AH, et al. N Engl J Med. 2004 Nov 4;351(19):1952-61. doi: 10.1056/NEJMoa042274. Epub 2004 Oct 31. N Engl J Med. 2004. PMID: 15516696 Clinical Trial.
• Concern for azotemia with angiotensin-converting enzyme inhibitors: public health implications and clinical relevance.

  Bart BA. Bart BA. Am Heart J. 1999 Nov;138(5 Pt 1):801-3. doi: 10.1016/s0002-8703(99)70001-3. Am Heart J. 1999. PMID: 10539807 Review. No abstract available.
• Lisinopril and renal failure.

  Heeg JE, de Jong PE, de Zeeuw D. Heeg JE, et al. Lancet. 1989 Apr 15;1(8642):846. doi: 10.1016/s0140-6736(89)92303-9. Lancet. 1989. PMID: 2564931 No abstract available.
• [Therapy with ACE inhibitors in chronic heart failure and limited kidney function].

  Osterziel KJ, Nagel F, Dietz R. Osterziel KJ, et al. Z Kardiol. 1994;83 Suppl 4:81-7. Z Kardiol. 1994. PMID: 7856286 Clinical Trial. German.
• Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?

  Frank GJ. Frank GJ. J Hypertens Suppl. 1989 Sep;7(5):S17-22. J Hypertens Suppl. 1989. PMID: 2553900 Review.